Drug Profile
Esomeprazole/naproxen - AstraZeneca/Old API Wind down
Alternative Names: esomeprazole magnesium trihydrate/naproxen; Naproxen/esomeprazole; naproxen/esomeprazole magnesium trihydrate; PN-400; VimovoLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca; Cincinnati Children's Hospital Medical Center; POZEN
- Developer AstraZeneca; Horizon Pharma; Old API Wind-down Ltd
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors; Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis
- No development reported Juvenile rheumatoid arthritis
Most Recent Events
- 28 Feb 2022 United States District Court for the District of New Jersey granted motion for Summary Judgment, for patents invalid in USA
- 28 Jul 2021 No recent reports of development identified for clinical-Phase-Unknown development in Juvenile-rheumatoid-arthritis in USA (PO)
- 18 Dec 2020 Nuvo Pharmaceuticals is now called Miravo Healthcare